Lazard Asset Management
MRNA icon

Lazard Asset Management’s Moderna MRNA Stock Holding History

Lazard Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$989K Buy
14,126
+2,762
+24% +$143K ﹤0.01% 1231
2026
Q1 		$577K Buy
+11,364
New +$530K ﹤0.01% 1332
2025
Q1 		– Sell
-2,669
Closed -$110K – 2471
2024
Q4 		$110K Sell
2,669
-11,516
-81% -$550K ﹤0.01% 1780
2024
Q3 		$947K Sell
14,185
-36,937
-72% -$3.39M ﹤0.01% 1099
2024
Q2 		$6.07M Buy
51,122
+40,951
+403% +$5.18M 0.01% 634
2024
Q1 		$1.08M Buy
10,171
+4,563
+81% +$460K ﹤0.01% 912
2023
Q4 		$556K Sell
5,608
-2,409
-30% -$203K ﹤0.01% 1083
2023
Q3 		$827K Buy
8,017
+1,078
+16% +$120K ﹤0.01% 1019
2023
Q2 		$842K Sell
6,939
-9,654
-58% -$1.29M ﹤0.01% 1023
2023
Q1 		$2.55M Buy
16,593
+510
+3% +$84.1K ﹤0.01% 871
2022
Q4 		$2.89M Sell
16,083
-43,824
-73% -$7.17M ﹤0.01% 834
2022
Q3 		$7.08M Buy
59,907
+19,799
+49% +$3M 0.01% 638
2022
Q2 		$5.73M Buy
40,108
+23,274
+138% +$3.33M 0.01% 709
2022
Q1 		$2.9M Sell
16,834
-29,655
-64% -$4.99M ﹤0.01% 838
2021
Q4 		$11.8M Sell
46,489
-43,500
-48% -$12.7M 0.01% 593
2021
Q3 		$34.6M Buy
89,989
+506
+0.6% +$187K 0.04% 357
2021
Q2 		$21M Buy
89,483
+69,859
+356% +$12.5M 0.02% 456
2021
Q1 		$2.57M Buy
19,624
+16,995
+646% +$2.46M ﹤0.01% 757
2020
Q4 		$274K Buy
+2,629
New +$266K ﹤0.01% 1058

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Lazard Asset Management's MRNA Position: Q2 2026 in Review

Lazard Asset Management increased its Moderna (MRNA) stake by 24% in Q2 2026, buying an estimated $143K and bringing the position to 14,126 shares worth $989K. The position accounts for ﹤0.01% of the portfolio, ranked #1231.

Lazard Asset Management first reported a position in MRNA in Q4 2020 and has held it in 19 quarters since. The position peaked at $34.6M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Lazard Asset Management held 14,126 shares of Moderna worth $989K as of Q2 2026.
  • Lazard Asset Management bought 2,762 Moderna shares in Q2 2026, an estimated $143K.
  • Moderna made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1231 holding.
  • Lazard Asset Management first reported a position in Moderna in Q4 2020 and has held it in 19 quarters since.
  • Lazard Asset Management's Moderna position peaked at $34.6M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.